Palatin Obtains Imaging Agent Approval, Aims For General Infection Nod
This article was originally published in The Gray Sheet
Executive Summary
Palatin/Mallinckrodt's NeutroSpec imaging agent will be available in mid-August, following FDA approval July 2 for diagnosing equivocal appendicitis in patients aged five years and older with atypical symptoms